Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies

Ähnliche Einträge

• Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
  von: Jiaxin Zhong, et al.
  Veröffentlicht: (2025)
• An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
  von: Zhuolin Zhou, et al.
  Veröffentlicht: (2025)
• Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
  von: Wenxiao Fan, et al.
  Veröffentlicht: (2025)
• Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
  von: Yuqing Ma, et al.
  Veröffentlicht: (2025)
• Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
  von: Claudio Maffeis, et al.
  Veröffentlicht: (2024)